Anaphylactic shock following the diagnosis of coronavirus disease 2019.
Identifieur interne : 000940 ( Main/Exploration ); précédent : 000939; suivant : 000941Anaphylactic shock following the diagnosis of coronavirus disease 2019.
Auteurs : Alberto Alvarez-Perea [Espagne] ; María Luisa Baeza [Espagne]Source :
- Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology [ 1534-4436 ] ; 2020.
Descripteurs français
- KwdFr :
- Anaphylaxie (anatomopathologie), Anaphylaxie (diagnostic), Anaphylaxie (traitement médicamenteux), Anaphylaxie (étiologie), Antiviraux (usage thérapeutique), Asthme (anatomopathologie), Asthme (complications), Asthme (diagnostic), Asthme (traitement médicamenteux), Betacoronavirus (effets des médicaments et des substances chimiques), Betacoronavirus (immunologie), Betacoronavirus (pathogénicité), Céfixime (effets indésirables), Femelle (MeSH), Ferritines (sang), Hormones corticosurrénaliennes (usage thérapeutique), Humains (MeSH), Hypertension artérielle (anatomopathologie), Hypertension artérielle (complications), Hypertension artérielle (diagnostic), Hypertension artérielle (traitement médicamenteux), Infections à coronavirus (anatomopathologie), Infections à coronavirus (complications), Infections à coronavirus (diagnostic), Infections à coronavirus (traitement médicamenteux), Issue fatale (MeSH), Marqueurs biologiques (sang), Pandémies (MeSH), Pneumopathie virale (anatomopathologie), Pneumopathie virale (complications), Pneumopathie virale (diagnostic), Pneumopathie virale (traitement médicamenteux), Produits de dégradation de la fibrine et du fibrinogène (métabolisme), Sujet âgé (MeSH), Évolution de la maladie (MeSH).
- MESH :
- anatomopathologie : Anaphylaxie, Asthme, Hypertension artérielle, Infections à coronavirus, Pneumopathie virale.
- diagnostic : Anaphylaxie, Asthme, Hypertension artérielle, Infections à coronavirus, Pneumopathie virale.
- effets des médicaments et des substances chimiques : Betacoronavirus.
- effets indésirables : Asthme, Céfixime, Hypertension artérielle, Infections à coronavirus, Pneumopathie virale.
- immunologie : Betacoronavirus.
- métabolisme : Produits de dégradation de la fibrine et du fibrinogène.
- pathogénicité : Betacoronavirus.
- sang : Ferritines, Marqueurs biologiques.
- traitement médicamenteux : Anaphylaxie, Asthme, Hypertension artérielle, Infections à coronavirus, Pneumopathie virale.
- usage thérapeutique : Antiviraux, Hormones corticosurrénaliennes.
- étiologie : Anaphylaxie.
- Femelle, Humains, Issue fatale, Pandémies, Sujet âgé, Évolution de la maladie.
English descriptors
- KwdEn :
- Adrenal Cortex Hormones (therapeutic use), Aged (MeSH), Anaphylaxis (diagnosis), Anaphylaxis (drug therapy), Anaphylaxis (etiology), Anaphylaxis (pathology), Antiviral Agents (therapeutic use), Asthma (complications), Asthma (diagnosis), Asthma (drug therapy), Asthma (pathology), Betacoronavirus (drug effects), Betacoronavirus (immunology), Betacoronavirus (pathogenicity), Biomarkers (blood), Cefixime (adverse effects), Coronavirus Infections (complications), Coronavirus Infections (diagnosis), Coronavirus Infections (drug therapy), Coronavirus Infections (pathology), Disease Progression (MeSH), Fatal Outcome (MeSH), Female (MeSH), Ferritins (blood), Fibrin Fibrinogen Degradation Products (metabolism), Humans (MeSH), Hypertension (complications), Hypertension (diagnosis), Hypertension (drug therapy), Hypertension (pathology), Pandemics (MeSH), Pneumonia, Viral (complications), Pneumonia, Viral (diagnosis), Pneumonia, Viral (drug therapy), Pneumonia, Viral (pathology).
- MESH :
- chemical , adverse effects : Cefixime.
- chemical , blood : Biomarkers, Ferritins.
- chemical , metabolism : Fibrin Fibrinogen Degradation Products.
- chemical , therapeutic use : Adrenal Cortex Hormones, Antiviral Agents.
- complications : Asthma, Coronavirus Infections, Hypertension, Pneumonia, Viral.
- diagnosis : Anaphylaxis, Asthma, Coronavirus Infections, Hypertension, Pneumonia, Viral.
- drug effects : Betacoronavirus.
- drug therapy : Anaphylaxis, Asthma, Coronavirus Infections, Hypertension, Pneumonia, Viral.
- etiology : Anaphylaxis.
- immunology : Betacoronavirus.
- pathogenicity : Betacoronavirus.
- pathology : Anaphylaxis, Asthma, Coronavirus Infections, Hypertension, Pneumonia, Viral.
- Aged, Disease Progression, Fatal Outcome, Female, Humans, Pandemics.
DOI: 10.1016/j.anai.2020.07.032
PubMed: 32745608
PubMed Central: PMC7395240
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Anaphylactic shock following the diagnosis of coronavirus disease 2019.</title>
<author><name sortKey="Alvarez Perea, Alberto" sort="Alvarez Perea, Alberto" uniqKey="Alvarez Perea A" first="Alberto" last="Alvarez-Perea">Alberto Alvarez-Perea</name>
<affiliation wicri:level="3"><nlm:affiliation>Allergy Service, Hospital General Universitario Gregorio Marañón, Madrid, Spain; Gregorio Marañón Health Research Institute, Madrid, Spain. Electronic address: alberto@alvarezperea.com.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Allergy Service, Hospital General Universitario Gregorio Marañón, Madrid, Spain; Gregorio Marañón Health Research Institute, Madrid</wicri:regionArea>
<placeName><settlement type="city">Madrid</settlement>
<region nuts="2" type="region">Communauté de Madrid</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Baeza, Maria Luisa" sort="Baeza, Maria Luisa" uniqKey="Baeza M" first="María Luisa" last="Baeza">María Luisa Baeza</name>
<affiliation wicri:level="3"><nlm:affiliation>Allergy Service, Hospital General Universitario Gregorio Marañón, Madrid, Spain; Gregorio Marañón Health Research Institute, Madrid, Spain; Biomedical Research Network on Rare Diseases (CIBERER)-U761, Madrid, Spain.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Allergy Service, Hospital General Universitario Gregorio Marañón, Madrid, Spain; Gregorio Marañón Health Research Institute, Madrid, Spain; Biomedical Research Network on Rare Diseases (CIBERER)-U761, Madrid</wicri:regionArea>
<placeName><settlement type="city">Madrid</settlement>
<region nuts="2" type="region">Communauté de Madrid</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:32745608</idno>
<idno type="pmid">32745608</idno>
<idno type="doi">10.1016/j.anai.2020.07.032</idno>
<idno type="pmc">PMC7395240</idno>
<idno type="wicri:Area/Main/Corpus">000859</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000859</idno>
<idno type="wicri:Area/Main/Curation">000859</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000859</idno>
<idno type="wicri:Area/Main/Exploration">000859</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Anaphylactic shock following the diagnosis of coronavirus disease 2019.</title>
<author><name sortKey="Alvarez Perea, Alberto" sort="Alvarez Perea, Alberto" uniqKey="Alvarez Perea A" first="Alberto" last="Alvarez-Perea">Alberto Alvarez-Perea</name>
<affiliation wicri:level="3"><nlm:affiliation>Allergy Service, Hospital General Universitario Gregorio Marañón, Madrid, Spain; Gregorio Marañón Health Research Institute, Madrid, Spain. Electronic address: alberto@alvarezperea.com.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Allergy Service, Hospital General Universitario Gregorio Marañón, Madrid, Spain; Gregorio Marañón Health Research Institute, Madrid</wicri:regionArea>
<placeName><settlement type="city">Madrid</settlement>
<region nuts="2" type="region">Communauté de Madrid</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Baeza, Maria Luisa" sort="Baeza, Maria Luisa" uniqKey="Baeza M" first="María Luisa" last="Baeza">María Luisa Baeza</name>
<affiliation wicri:level="3"><nlm:affiliation>Allergy Service, Hospital General Universitario Gregorio Marañón, Madrid, Spain; Gregorio Marañón Health Research Institute, Madrid, Spain; Biomedical Research Network on Rare Diseases (CIBERER)-U761, Madrid, Spain.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Allergy Service, Hospital General Universitario Gregorio Marañón, Madrid, Spain; Gregorio Marañón Health Research Institute, Madrid, Spain; Biomedical Research Network on Rare Diseases (CIBERER)-U761, Madrid</wicri:regionArea>
<placeName><settlement type="city">Madrid</settlement>
<region nuts="2" type="region">Communauté de Madrid</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j">Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology</title>
<idno type="eISSN">1534-4436</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adrenal Cortex Hormones (therapeutic use)</term>
<term>Aged (MeSH)</term>
<term>Anaphylaxis (diagnosis)</term>
<term>Anaphylaxis (drug therapy)</term>
<term>Anaphylaxis (etiology)</term>
<term>Anaphylaxis (pathology)</term>
<term>Antiviral Agents (therapeutic use)</term>
<term>Asthma (complications)</term>
<term>Asthma (diagnosis)</term>
<term>Asthma (drug therapy)</term>
<term>Asthma (pathology)</term>
<term>Betacoronavirus (drug effects)</term>
<term>Betacoronavirus (immunology)</term>
<term>Betacoronavirus (pathogenicity)</term>
<term>Biomarkers (blood)</term>
<term>Cefixime (adverse effects)</term>
<term>Coronavirus Infections (complications)</term>
<term>Coronavirus Infections (diagnosis)</term>
<term>Coronavirus Infections (drug therapy)</term>
<term>Coronavirus Infections (pathology)</term>
<term>Disease Progression (MeSH)</term>
<term>Fatal Outcome (MeSH)</term>
<term>Female (MeSH)</term>
<term>Ferritins (blood)</term>
<term>Fibrin Fibrinogen Degradation Products (metabolism)</term>
<term>Humans (MeSH)</term>
<term>Hypertension (complications)</term>
<term>Hypertension (diagnosis)</term>
<term>Hypertension (drug therapy)</term>
<term>Hypertension (pathology)</term>
<term>Pandemics (MeSH)</term>
<term>Pneumonia, Viral (complications)</term>
<term>Pneumonia, Viral (diagnosis)</term>
<term>Pneumonia, Viral (drug therapy)</term>
<term>Pneumonia, Viral (pathology)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Anaphylaxie (anatomopathologie)</term>
<term>Anaphylaxie (diagnostic)</term>
<term>Anaphylaxie (traitement médicamenteux)</term>
<term>Anaphylaxie (étiologie)</term>
<term>Antiviraux (usage thérapeutique)</term>
<term>Asthme (anatomopathologie)</term>
<term>Asthme (complications)</term>
<term>Asthme (diagnostic)</term>
<term>Asthme (traitement médicamenteux)</term>
<term>Betacoronavirus (effets des médicaments et des substances chimiques)</term>
<term>Betacoronavirus (immunologie)</term>
<term>Betacoronavirus (pathogénicité)</term>
<term>Céfixime (effets indésirables)</term>
<term>Femelle (MeSH)</term>
<term>Ferritines (sang)</term>
<term>Hormones corticosurrénaliennes (usage thérapeutique)</term>
<term>Humains (MeSH)</term>
<term>Hypertension artérielle (anatomopathologie)</term>
<term>Hypertension artérielle (complications)</term>
<term>Hypertension artérielle (diagnostic)</term>
<term>Hypertension artérielle (traitement médicamenteux)</term>
<term>Infections à coronavirus (anatomopathologie)</term>
<term>Infections à coronavirus (complications)</term>
<term>Infections à coronavirus (diagnostic)</term>
<term>Infections à coronavirus (traitement médicamenteux)</term>
<term>Issue fatale (MeSH)</term>
<term>Marqueurs biologiques (sang)</term>
<term>Pandémies (MeSH)</term>
<term>Pneumopathie virale (anatomopathologie)</term>
<term>Pneumopathie virale (complications)</term>
<term>Pneumopathie virale (diagnostic)</term>
<term>Pneumopathie virale (traitement médicamenteux)</term>
<term>Produits de dégradation de la fibrine et du fibrinogène (métabolisme)</term>
<term>Sujet âgé (MeSH)</term>
<term>Évolution de la maladie (MeSH)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Cefixime</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Biomarkers</term>
<term>Ferritins</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Fibrin Fibrinogen Degradation Products</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Adrenal Cortex Hormones</term>
<term>Antiviral Agents</term>
</keywords>
<keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Anaphylaxie</term>
<term>Asthme</term>
<term>Hypertension artérielle</term>
<term>Infections à coronavirus</term>
<term>Pneumopathie virale</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Asthma</term>
<term>Coronavirus Infections</term>
<term>Hypertension</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Anaphylaxis</term>
<term>Asthma</term>
<term>Coronavirus Infections</term>
<term>Hypertension</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr"><term>Anaphylaxie</term>
<term>Asthme</term>
<term>Hypertension artérielle</term>
<term>Infections à coronavirus</term>
<term>Pneumopathie virale</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Betacoronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Anaphylaxis</term>
<term>Asthma</term>
<term>Coronavirus Infections</term>
<term>Hypertension</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="effets des médicaments et des substances chimiques" xml:lang="fr"><term>Betacoronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Asthme</term>
<term>Céfixime</term>
<term>Hypertension artérielle</term>
<term>Infections à coronavirus</term>
<term>Pneumopathie virale</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Anaphylaxis</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Betacoronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Betacoronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Produits de dégradation de la fibrine et du fibrinogène</term>
</keywords>
<keywords scheme="MESH" qualifier="pathogenicity" xml:lang="en"><term>Betacoronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="pathogénicité" xml:lang="fr"><term>Betacoronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Anaphylaxis</term>
<term>Asthma</term>
<term>Coronavirus Infections</term>
<term>Hypertension</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Ferritines</term>
<term>Marqueurs biologiques</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Anaphylaxie</term>
<term>Asthme</term>
<term>Hypertension artérielle</term>
<term>Infections à coronavirus</term>
<term>Pneumopathie virale</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antiviraux</term>
<term>Hormones corticosurrénaliennes</term>
</keywords>
<keywords scheme="MESH" qualifier="étiologie" xml:lang="fr"><term>Anaphylaxie</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Aged</term>
<term>Disease Progression</term>
<term>Fatal Outcome</term>
<term>Female</term>
<term>Humans</term>
<term>Pandemics</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Femelle</term>
<term>Humains</term>
<term>Issue fatale</term>
<term>Pandémies</term>
<term>Sujet âgé</term>
<term>Évolution de la maladie</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32745608</PMID>
<DateCompleted><Year>2020</Year>
<Month>10</Month>
<Day>13</Day>
</DateCompleted>
<DateRevised><Year>2020</Year>
<Month>10</Month>
<Day>13</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1534-4436</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>125</Volume>
<Issue>4</Issue>
<PubDate><Year>2020</Year>
<Month>10</Month>
</PubDate>
</JournalIssue>
<Title>Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology</Title>
<ISOAbbreviation>Ann Allergy Asthma Immunol</ISOAbbreviation>
</Journal>
<ArticleTitle>Anaphylactic shock following the diagnosis of coronavirus disease 2019.</ArticleTitle>
<Pagination><MedlinePgn>477-478</MedlinePgn>
</Pagination>
<ELocationID EIdType="pii" ValidYN="Y">S1081-1206(20)30521-4</ELocationID>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.anai.2020.07.032</ELocationID>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Alvarez-Perea</LastName>
<ForeName>Alberto</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>Allergy Service, Hospital General Universitario Gregorio Marañón, Madrid, Spain; Gregorio Marañón Health Research Institute, Madrid, Spain. Electronic address: alberto@alvarezperea.com.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Baeza</LastName>
<ForeName>María Luisa</ForeName>
<Initials>ML</Initials>
<AffiliationInfo><Affiliation>Allergy Service, Hospital General Universitario Gregorio Marañón, Madrid, Spain; Gregorio Marañón Health Research Institute, Madrid, Spain; Biomedical Research Network on Rare Diseases (CIBERER)-U761, Madrid, Spain.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2020</Year>
<Month>08</Month>
<Day>01</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Ann Allergy Asthma Immunol</MedlineTA>
<NlmUniqueID>9503580</NlmUniqueID>
<ISSNLinking>1081-1206</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000305">Adrenal Cortex Hormones</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D005338">Fibrin Fibrinogen Degradation Products</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C036309">fibrin fragment D</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>9007-73-2</RegistryNumber>
<NameOfSubstance UI="D005293">Ferritins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>97I1C92E55</RegistryNumber>
<NameOfSubstance UI="D020682">Cefixime</NameOfSubstance>
</Chemical>
</ChemicalList>
<SupplMeshList><SupplMeshName Type="Disease" UI="C000657245">COVID-19</SupplMeshName>
<SupplMeshName Type="Organism" UI="C000656484">severe acute respiratory syndrome coronavirus 2</SupplMeshName>
</SupplMeshList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000305" MajorTopicYN="N">Adrenal Cortex Hormones</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000707" MajorTopicYN="N">Anaphylaxis</DescriptorName>
<QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
<QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D001249" MajorTopicYN="N">Asthma</DescriptorName>
<QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
<QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="N">Betacoronavirus</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000472" MajorTopicYN="N">pathogenicity</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D020682" MajorTopicYN="N">Cefixime</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName>
<QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
<QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017809" MajorTopicYN="N">Fatal Outcome</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005293" MajorTopicYN="N">Ferritins</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005338" MajorTopicYN="N">Fibrin Fibrinogen Degradation Products</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006973" MajorTopicYN="N">Hypertension</DescriptorName>
<QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
<QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName>
<QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
<QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year>
<Month>06</Month>
<Day>15</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2020</Year>
<Month>07</Month>
<Day>27</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>8</Month>
<Day>4</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>8</Month>
<Day>4</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>8</Month>
<Day>4</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">32745608</ArticleId>
<ArticleId IdType="pii">S1081-1206(20)30521-4</ArticleId>
<ArticleId IdType="doi">10.1016/j.anai.2020.07.032</ArticleId>
<ArticleId IdType="pmc">PMC7395240</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Ann Allergy Asthma Immunol. 2020 Jun;124(6):550-557</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31881269</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Br J Dermatol. 2020 Jul;183(1):71-77</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32348545</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2020 Mar 28;395(10229):1054-1062</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32171076</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>World Allergy Organ J. 2014 May 30;7(1):9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24920969</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Allergy Clin Immunol Pract. 2020 Jul - Aug;8(7):2386-2387</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32387383</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Allergy Clin Immunol. 2020 Apr;145(4):1082-1123</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32001253</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Front Immunol. 2017 Jul 26;8:846</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28798744</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Espagne</li>
</country>
<region><li>Communauté de Madrid</li>
</region>
<settlement><li>Madrid</li>
</settlement>
</list>
<tree><country name="Espagne"><region name="Communauté de Madrid"><name sortKey="Alvarez Perea, Alberto" sort="Alvarez Perea, Alberto" uniqKey="Alvarez Perea A" first="Alberto" last="Alvarez-Perea">Alberto Alvarez-Perea</name>
</region>
<name sortKey="Baeza, Maria Luisa" sort="Baeza, Maria Luisa" uniqKey="Baeza M" first="María Luisa" last="Baeza">María Luisa Baeza</name>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidSeniorV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000940 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000940 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= CovidSeniorV1 |flux= Main |étape= Exploration |type= RBID |clé= pubmed:32745608 |texte= Anaphylactic shock following the diagnosis of coronavirus disease 2019. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:32745608" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \ | NlmPubMed2Wicri -a CovidSeniorV1
This area was generated with Dilib version V0.6.37. |